Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

On November 22, Kronos Bio Board Approved Approximately 83% Reduction In Its Workforce; Norbert Bischofberger Resigns As President And CEO, Effective December 3, 2024 - Filing

Author: Benzinga Newsdesk | November 27, 2024 06:08am

The workforce reduction is expected to be substantially completed on December 31, 2024.

In connection with the reduction in workforce, the Company expects to incur a charge of approximately $3.7 million relating to the cash-based expense of the employee severance, benefits, and related costs.

The Company anticipates payments associated with the workforce reduction will be substantially complete by the end of the first quarter of 2025.

On November 22, 2024, Deborah Knobelman, the Company's Chief Financial Officer and Chief Operating Officer, was appointed to serve as President and Interim Chief Executive Officer, effective December 3, 2024. Knobelman will also continue to serve as the Company's Chief Financial Officer and Chief Operating Officer.

Posted In: KRON

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist